Immunological characterization of plant-based HIV-1 Gag/Dgp41 virus-like particles

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Kessans, Sarah A ^a,b,c   Linhart, Mark D ^a,b   Meador, Lydia R ^a,b   Kilbourne, Jacquelyn ^b   Hogue, Brenda G ^a,b   Fromme, Petra ^b   Matoba, Nobuyuki ^a,b,d,e   Mor, Tsafrir S ^a,b  

^a ARIZONA STATE UNIVERSITY   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF CANTERBURY   (New Zealand)

^d Owensboro Cancer Research Program   (United States)

^e University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; GLYCOPROTEIN GP 41; GP41 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS LIKE PARTICLE VACCINE;

ANIMAL; ANTIBODY PRODUCTION; BAGG ALBINO MOUSE; DRUG EFFECT; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METABOLISM; MOUSE; TOBACCO; TRANSGENIC PLANT;

AIDS VACCINES; ANIMALS; ANTIBODY FORMATION; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; MICE; MICE, INBRED BALB C; PLANTS, GENETICALLY MODIFIED; TOBACCO; VACCINES, VIRUS-LIKE PARTICLE;

EID: 85018305114     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0151842     Document Type: Article

References (75)

1. Montero M, van Houten NE, Wang X, Scott JK. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol Mol Biol Rev. 2008; 72(1):54–84. PMID: 18322034. doi: 10.1128/MMBR.00020-07
2. Gong Z, Kessans SA, Song L, Dorner K, Lee HH, Meador LR, et al. Recombinant expression, purification, and biophysical characterization of the transmembrane and membrane proximal domains of HIV-1 gp41. Protein Sci. 2014; 23(11):1607–18. doi: 10.1002/pro.2540 PMID: 25155369; PubMed Central PMCID: PMC4241111.
3. Alfsen A, Iniguez P, Bouguyon E, Bomsel M. Secretory IgA Specific for a Conserved Epitope on gp41 Envelope Glycoprotein Inhibits Epithelial Transcytosis of HIV-1. J Immunol. 2001; 166(10):6257–65. PMID: 11342649.
4. Sagar M, Akiyama H, Etemad B, Ramirez N, Freitas I, Gummuluru S. Transmembrane Domain Membrane Proximal External Region but Not Surface Unit-Directed Broadly Neutralizing HIV-1 Antibodies Can Restrict Dendritic Cell-Mediated HIV-1 Trans-infection. J Infect Dis. 2012; 205(8):1248–57. Epub 2012/03/08. jis183 [pii] doi: 10.1093/infdis/jis183 PMID: 22396600; PubMed Central PMCID: PMC3308909.
5. Magerus-Chatinet A, Yu H, Garcia S, Ducloux E, Terris B, Bomsel M. Galactosyl ceramide expressed on dendritic cells can mediate HIV-1 transfer from monocyte derived dendritic cells to autologous T cells. Virology. 2007; 362(1):67–74. PMID: 17234232.
6. Matoba N, Geyer BC, Kilbourne J, Alfsen A, Bomsel M, Mor TS. Humoral immune responses by prime-boost heterologous route immunizations with CTB-MPR(649–684), a mucosal subunit HIV/AIDS vaccine candidate. Vaccine. 2006; 24:5047–55. PMID: 16621185.
7. Matoba N, Magerus A, Geyer BC, Zhang Y, Muralidharan M, Alfsen A, et al. A mucosally targeted subunit vaccine candidate eliciting HIV-1 transcytosis-blocking Abs. Proc Natl Acad Sci U S A. 2004; 101 (37):13584–9. PMID: 15347807.
8. Broliden K, Hinkula J, Devito C, Kiama P, Kimani J, Trabbatoni D, et al. Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers. Immunol Lett. 2001; 79(1–2):29–36. PMID: 11595287.
9. Devito C, Broliden K, Kaul R, Svensson L, Johansen K, Kiama P, et al. Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J Immunol. 2000; 165(9):5170–6. PMID: 11046049.
10. Kaul R, Plummer F, Clerici M, Bomsel M, Lopalco L, Broliden K. Mucosal IgA in exposed, uninfected subjects: evidence for a role in protection against HIV infection. Aids. 2001; 15(3):431–2. PMID: 11273233.
11. Benjelloun F, Dawood R, Urcuqui-Inchima S, Rochereau N, Chanut B, Verrier B, et al. Secretory IgA specific for MPER can protect from HIV-1 infection in vitro. AIDS. 2013; 27(12):1992–5. Epub 2013/05/ 23. doi: 10.1097/QAD.0b013e3283632ea1 PMID: 23696073.
12. Zwick MB, Jensen R, Church S, Wang M, Stiegler G, Kunert R, et al. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J Virol. 2005; 79(2):1252–61. doi: 10.1128/JVI.79.2.1252-1261.2005 PMID: 15613352; PubMed Central PMCID: PMC538539.
13. Hessell AJ, Rakasz EG, Tehrani DM, Huber M, Weisgrau KL, Landucci G, et al. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. Journal of virology. 2010; 84(3):1302–13. Epub 2009/11/13. doi: 10.1128/JVI. 01272-09 PMID: 19906907; PubMed Central PMCID: PMC2812338.
14. Kwong PD, Mascola JR. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity. 2012; 37(3):412–25. Epub 2012/09/25. doi: 10.1016/j.immuni.2012.08.012 PMID: 22999947.
15. Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, Longo NS, et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature. 2012; 491(7424):406–12. Epub 2012/11/16. doi: 10.1038/nature11544 PMID: 23151583.
16. Bouvin-Pley M, Morgand M, Meyer L, Goujard C, Moreau A, Mouquet H, et al. Drift of the HIV-1 envelope glycoprotein gp120 toward increased neutralization resistance over the course of the epidemic: a comprehensive study using the most potent and broadly neutralizing monoclonal antibodies. J Virol. 2014; 88(23):13910–7. doi: 10.1128/JVI.02083-14 PMID: 25231299; PubMed Central PMCID: PMC4248973.
17. Dennison SM, Sutherland LL, Jaeger FH, Anasti KM, Parks R, Stewart S, et al. Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41. PLoS One. 2011; 6(11):e27824. doi: 10.1371/journal.pone.0027824 PMID: 22140469; PubMed Central PMCID: PMC3227606.
18. Pastori C, Tudor D, Diomede L, Drillet AS, Jegerlehner A, Rohn TA, et al. Virus like particle based strategy to elicit HIV-protective antibodies to the alpha-helic regions of gp41. Virology. 2012; 431(1–2):1–11. Epub 2012/06/05. doi: 10.1016/j.virol.2012.05.005 PMID: 22658900.
19. Leroux-Roels G, Maes C, Clement F, van Engelenburg F, van den Dobbelsteen M, Adler M, et al. Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes. PloS one. 2013; 8(2):e55438. Epub 2013/02/26. doi: 10.1371/journal.pone.0055438 PMID: 23437055; PubMed Central PMCID: PMC3577797.
20. Burton DR, Ahmed R, Barouch DH, Butera ST, Crotty S, Godzik A, et al. A Blueprint for HIV Vaccine Discovery. Cell host & microbe. 2012; 12(4):396–407. Epub 2012/10/23. doi: 10.1016/j.chom.2012.09. 008 PMID: 23084910; PubMed Central PMCID: PMC3513329.
21. Koff WC, Burton DR, Johnson PR, Walker BD, King CR, Nabel GJ, et al. Accelerating next-generation vaccine development for global disease prevention. Science. 2013; 340(6136):1232910. doi: 10.1126/ science.1232910 PMID: 23723240; PubMed Central PMCID: PMC4026248.
22. Verkoczy L, Kelsoe G, Haynes BF. HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development. PLoS Pathog. 2014; 10(5):e1004073. doi: 10.1371/journal.ppat.1004073 PMID: 24853821; PubMed Central PMCID: PMC4031215.
23. Ivankin A, Apellaniz B, Gidalevitz D, Nieva JL. Mechanism of membrane perturbation by the HIV-1 gp41 membrane-proximal external region and its modulation by cholesterol. Biochimica et biophysica acta. 2012; 1818(11):2521–8. Epub 2012/06/14. doi: 10.1016/j.bbamem.2012.06.002 PMID: 22692008.
24. Montero M, Gulzar N, Klaric KA, Donald JE, Lepik C, Wu S, et al. Neutralizing epitopes in the membrane-proximal external region of HIV-1 gp41 are influenced by the transmembrane domain and the plasma membrane. J Virol. 2012; 86(6):2930–41. Epub 2012/01/13. JVI.06349-11 [pii] doi: 10.1128/ JVI.06349-11 PMID: 22238313; PubMed Central PMCID: PMC3302331.
25. Ofek G, Zirkle B, Yang Y, Zhu Z, McKee K, Zhang B, et al. Structural basis for HIV-1 neutralization by 2F5-like antibodies m66 and m66.6. J Virol. 2014; 88(5):2426–41. doi: 10.1128/JVI.02837-13 PMID: 24335316; PubMed Central PMCID: PMC3958054.
26. Tumban E, Peabody J, Peabody DS, Chackerian B. A universal virus-like particle-based vaccine for human papillomavirus: longevity of protection and role of endogenous and exogenous adjuvants. Vaccine. 2013; 31(41):4647–54. doi: 10.1016/j.vaccine.2013.07.052 PMID: 23933337; PubMed Central PMCID: PMC3785330.
27. Balasubramaniam M, Freed EO. New insights into HIV assembly and trafficking. Physiology (Bethesda). 2011; 26(4):236–51. Epub 2011/08/16. doi: 10.1152/physiol.00051.2010 PMID: 21841072.
28. Gheysen D, Jacobs E, de Foresta F, Thiriart C, Francotte M, Thines D, et al. Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell. 1989; 59(1):103–12. PMID: 2676191.
29. Addo MM, Yu XG, Rathod A, Cohen D, Eldridge RL, Strick D, et al. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol. 2003; 77(3):2081–92. PMID: 12525643.
30. Doan LX, Li M, Chen C, Yao Q. Virus-like particles as HIV-1 vaccines. Rev Med Virol. 2005; 15(2):75–88. PMID: 15484204.
31. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, Moodley E, et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med. 2007; 13 (1):46–53. doi: 10.1038/nm1520 PMID: 17173051.
32. Hicar MD, Chen X, Briney B, Hammonds J, Wang JJ, Kalams S, et al. Pseudovirion particles bearing native HIV envelope trimers facilitate a novel method for generating human neutralizing monoclonal antibodies against HIV. J Acquir Immune Defic Syndr. 2010; 54(3):223–35. doi: 10.1097/QAI. 0b013e3181dc98a3 PMID: 20531016; PubMed Central PMCID: PMC2930513.
33. Montefiori DC, Safrit JT, Lydy SL, Barry AP, Bilska M, Vo HT, et al. Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques. J Virol. 2001; 75(13):5879–90. doi: 10.1128/JVI.75.13.5879-5890.2001 PMID: 11390589; PubMed Central PMCID: PMC114303.
34. Williamson AL, Rybicki EP. Justification for the inclusion of Gag in HIV vaccine candidates. Expert Rev Vaccines. 2015:1–14. doi: 10.1586/14760584.2016.1129904 PMID: 26645951.
35. Zimran A, Gonzalez-Rodriguez DE, Abrahamov A, Elstein D, Paz A, Brill-Almon E, et al. Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease. Blood Cells Mol Dis. 2015; 54(1):9–16. doi: 10.1016/j.bcmd.2014.10.002 PMID: 25453586.
36. Zhang Y, Li D, Jin X, Huang Z. Fighting Ebola with ZMapp: spotlight on plant-made antibody. Science China Life sciences. 2014; 57(10):987–8. doi: 10.1007/s11427-014-4746-7 PMID: 25218825.
37. Lyon GM, Mehta AK, Varkey JB, Brantly K, Plyler L, McElroy AK, et al. Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med. 2014; 371(25):2402–9. doi: 10.1056/ NEJMoa1409838 PMID: 25390460.
38. Kuehn BM. As Ebola Epidemic Begins to Slow, Trials of Drugs and Vaccines Speed Up. JAMA. 2015. doi: 10.1001/jama.2015.0942 PMID: 25671623.
39. Rybicki EP. Plant-based vaccines against viruses. Virology journal. 2014; 11(1):205. doi: 10.1186/ s12985-014-0205-0 PMID: 25465382; PubMed Central PMCID: PMC4264547.
40. Kessans SA, Linhart MD, Matoba N, Mor T. Biological and biochemical characterization of HIV-1 Gag/ dgp41 virus-like particles expressed in Nicotiana benthamiana. Plant Biotechnology Journal. 2013; 11 (6):681–90. doi: 10.1111/pbi.12058 PMID: 23506331
41. Matoba N, Griffin TA, Mittman M, Doran JD, Alfsen A, Montefiori DC, et al. Transcytosis-blocking abs elicited by an oligomeric immunogen based on the membrane proximal region of HIV-1 gp41 target non-neutralizing epitopes. Curr HIV Res. 2008; 6(3):218–29. PMID: 18473785.
42. Mor TS, Sternfeld M, Soreq H, Arntzen CJ, Mason HS. Expression of recombinant human acetylcholinesterase in transgenic tomato plants. Biotechnol Bioeng. 2001; 75(3):259–66. PMID: 11590598.
43. Leary S, Underwood W, Anthony R, Cartner S, Corey D, Grandin T, et al. AVMA guidelines for the euthanasia of animals: 2013 edition (Available at: https://www.avma.org/KB/Policies/Documents/euthanasia.pdf). Schaumburg, IL: American Veterinary Medical Association; 2013. 102 p.
44. Shen R, Drelichman ER, Bimczok D, Ochsenbauer C, Kappes JC, Cannon JA, et al. GP41-specific antibody blocks cell-free HIV type 1 transcytosis through human rectal mucosa and model colonic epithelium. J Immunol. 2010; 184(7):3648–55. Epub 2010/03/09. doi: 10.4049/jimmunol.0903346 PMID: 20208001; PubMed Central PMCID: PMC3731077.
45. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley JM, et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol. 2001; 75(22):10892–905. doi: 10.1128/JVI.75.22.10892-10905.2001 PMID: 11602729; PubMed Central PMCID: PMC114669.
46. Tudor D, Derrien M, Diomede L, Drillet AS, Houimel M, Moog C, et al. HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis. Mucosal Immunol. 2009; 2(5):412–26. Epub 2009/07/10. mi200989 [pii] doi: 10.1038/mi.2009.89 PMID: 19587640.
47. Tudor D, Bomsel M. The broadly neutralizing HIV-1 IgG 2F5 elicits gp41-specific antibody-dependent cell cytotoxicity in a FcgammaRI-dependent manner. AIDS. 2011; 25(6):751–9. doi: 10.1097/QAD. 0b013e32834507bd PMID: 21330910.
48. Wang J, Xu L, Tong P, Chen YH. Mucosal antibodies induced by tandem repeat of 2F5 epitope block transcytosis of HIV-1. Vaccine. 2011; 29(47):8542–8. Epub 2011/09/24. doi: 10.1016/j.vaccine.2011. 09.032 PMID: 21939723.
49. Zhou M, Kostoula I, Brill B, Panou E, Sakarellos-Daitsiotis M, Dietrich U. Prime boost vaccination approaches with different conjugates of a new HIV-1 gp41 epitope encompassing the membrane proximal external region induce neutralizing antibodies in mice. Vaccine. 2012; 30(11):1911–6. Epub 2012/ 01/25. S0264-410X(12)00041-2 [pii] doi: 10.1016/j.vaccine.2012.01.026 PMID: 22269872.
50. Matoba N, Shah NR, Mor TS. Humoral immunogenicity of an HIV-1 envelope residue 649–684 membrane-proximal region peptide fused to the plague antigen F1-V. Vaccine. 2011; 29(34):5584–90. Epub 2011/06/23. S0264-410X(11)00871-1 [pii] doi: 10.1016/j.vaccine.2011.06.007 PMID: 21693158; PubMed Central PMCID: PMC3152316.
51. Verkoczy L, Chen Y, Zhang J, Bouton-Verville H, Newman A, Lockwood B, et al. Induction of HIV-1 broad neutralizing antibodies in 2F5 knock-in mice: selection against membrane proximal external region-associated autoreactivity limits T-dependent responses. Journal of immunology. 2013; 191 (5):2538–50. Epub 2013/08/07. doi: 10.4049/jimmunol.1300971 PMID: 23918977; PubMed Central PMCID: PMC3870053.
52. Bomsel M, Tudor D, Drillet AS, Alfsen A, Ganor Y, Roger MG, et al. Immunization with HIV-1 gp41 Subunit Virosomes Induces Mucosal Antibodies Protecting Nonhuman Primates against Vaginal SHIV Challenges. Immunity. 2011; 34(2):269–80. Epub 2011/02/15. S1074-7613(11)00036-7 [pii] doi: 10. 1016/j.immuni.2011.01.015 PMID: 21315623.
53. Frey G, Peng H, Rits-Volloch S, Morelli M, Cheng Y, Chen B. A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. P Natl Acad Sci USA. 2008; 105(10):3739–44. Epub 2008/ 03/07. doi: 10.1073/pnas.0800255105 PMID: 18322015; PubMed Central PMCID: PMC2268799.
54. Haynes BF, Verkoczy L. AIDS/HIV. Host controls of HIV neutralizing antibodies. Science. 2014; 344 (6184):588–9. doi: 10.1126/science.1254990 PMID: 24812389; PubMed Central PMCID: PMC4162091.
55. Gong Z, Martin-Garcia JM, Daskalova SM, Craciunescu FM, Song L, Dorner K, et al. Biophysical Characterization of a Vaccine Candidate against HIV-1: The Transmembrane and Membrane Proximal Domains of HIV-1 gp41 as a Maltose Binding Protein Fusion. PLoS One. 2015; 10(8):e0136507. doi: 10.1371/journal.pone.0136507 PMID: 26295457; PubMed Central PMCID: PMCPMC4546420.
56. Hammonds J, Chen X, Zhang X, Lee F, Spearman P. Advances in methods for the production, purification, and characterization of HIV-1 Gag-Env pseudovirion vaccines. Vaccine. 2007; 25(47):8036–48. doi: 10.1016/j.vaccine.2007.09.016 PMID: 17936444.
57. Rybicki EP. Plant-made vaccines for humans and animals. Plant Biotechnol J. 2010; 8(5):620–37. Epub 2010/03/18. PBI507 [pii] doi: 10.1111/j.1467-7652.2010.00507.x PMID: 20233333.
58. Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014; 514(7520):47–53. doi: 10.1038/nature13777 PMID: 25171469; PubMed Central PMCID: PMC4214273.
59. McCarthy M. US signs contract with ZMapp maker to accelerate development of the Ebola drug. Bmj. 2014; 349:g5488. doi: 10.1136/bmj.g5488 PMID: 25189475.
60. Thanavala Y, Mahoney M, Pal S, Scott A, Richter L, Natarajan N, et al. Immunogenicity in humans of an edible vaccine for hepatitis B. Proc Natl Acad Sci U S A. 2005; 102(9):3378–82. PMID: 15728371.
61. Huang Z, Chen Q, Hjelm B, Arntzen C, Mason H. A DNA replicon system for rapid high-level production of virus-like particles in plants. Biotechnology and bioengineering. 2009; 103(4):706–14. Epub 2009/ 03/25. doi: 10.1002/bit.22299 PMID: 19309755; PubMed Central PMCID: PMC2704498.
62. Santi L, Batchelor L, Huang Z, Hjelm B, Kilbourne J, Arntzen CJ, et al. An efficient plant viral expression system generating orally immunogenic Norwalk virus-like particles. Vaccine. 2008; 26(15):1846–54. Epub 2008/03/08. doi: 10.1016/j.vaccine.2008.01.053 PMID: 18325641; PubMed Central PMCID: PMC2744496.
63. Zhang X, Buehner NA, Hutson AM, Estes MK, Mason HS. Tomato is a highly effective vehicle for expression and oral immunization with Norwalk virus capsid protein. Plant biotechnology journal. 2006; 4(4):419–32. Epub 2006/12/21. doi: 10.1111/j.1467-7652.2006.00191.x PMID: 17177807.
64. D'Aoust MA, Couture MM, Charland N, Trepanier S, Landry N, Ors F, et al. The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. Plant biotechnology journal. 2010; 8(5):607–19. Epub 2010/03/05. doi: 10.1111/j.1467-7652.2009. 00496.x PMID: 20199612.
65. Meyers A, Chakauya E, Shephard E, Tanzer FL, Maclean J, Lynch A, et al. Expression of HIV-1 antigens in plants as potential subunit vaccines. BMC Biotechnol. 2008; 8:53. doi: 10.1186/1472-6750-8-53 PMID: 18573204; PubMed Central PMCID: PMC2443125.
66. Scotti N, Alagna F, Ferraiolo E, Formisano G, Sannino L, Buonaguro L, et al. High-level expression of the HIV-1 Pr55gag polyprotein in transgenic tobacco chloroplasts. Planta. 2009; 229(5):1109–22. PMID: 19234717. doi: 10.1007/s00425-009-0898-2
67. Guetard D, Greco R, Cervantes Gonzalez M, Celli S, Kostrzak A, Langlade-Demoyen P, et al. Immunogenicity and tolerance following HIV-1/HBV plant-based oral vaccine administration. Vaccine. 2008; 26 (35):4477–85. Epub 2008/07/08. S0264-410X(08)00806-2 [pii] doi: 10.1016/j.vaccine.2008.06.059 PMID: 18601967.
68. Perez-Filgueira DM, Brayfield BP, Phiri S, Borca MV, Wood C, Morris TJ. Preserved antigenicity of HIV-1 p24 produced and purified in high yields from plants inoculated with a tobacco mosaic virus (TMV)-derived vector. Journal of virological methods. 2004; 121(2):201–8. Epub 2004/09/24. doi: 10. 1016/j.jviromet.2004.06.022 PMID: 15381357.
69. Gonzalez-Rabade N, McGowan EG, Zhou F, McCabe MS, Bock R, Dix PJ, et al. Immunogenicity of chloroplast-derived HIV-1 p24 and a p24-Nef fusion protein following subcutaneous and oral administration in mice. Plant biotechnology journal. 2011; 9(6):629–38. Epub 2011/03/30. doi: 10.1111/j.1467-7652.2011.00609.x PMID: 21443546.
70. Lindh I, Kalbina I, Thulin S, Scherbak N, Savenstrand H, Brave A, et al. Feeding of mice with Arabidopsis thaliana expressing the HIV-1 subtype C p24 antigen gives rise to systemic immune responses. Apmis. 2008; 116(11):985–94. Epub 2009/01/10. doi: 10.1111/j.1600-0463.2008.00900.x PMID: 19132995.
71. Durrani Z, McInerney TL, McLain L, Jones T, Bellaby T, Brennan FR, et al. Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1specific IgA and IgG than oral immunization. J Immunol Methods. 1998; 220(1–2):93–103. PMID: 9839930.
72. Marusic C, Rizza P, Lattanzi L, Mancini C, Spada M, Belardelli F, et al. Chimeric plant virus particles as immunogens for inducing murine and human immune responses against human immunodeficiency virus type 1. J Virol. 2001; 75(18):8434–9. PMID: 11507188.
73. 649 684. Plant Biotechnol J. 2009; 7(2):129–45. PMID: 19037902. doi: 10.1111/j.1467-7652.2008.00381.x
74. McInerney TL, Brennan FR, Jones TD, Dimmock NJ. Analysis of the ability of five adjuvants to enhance immune responses to a chimeric plant virus displaying an HIV-1 peptide. Vaccine. 1999; 17(11–12):1359–68. PMID: 10195771.
75. McLain L, Durrani Z, Wisniewski LA, Porta C, Lomonossoff GP, Dimmock NJ. Stimulation of neutralizing antibodies to human immunodeficiency virus type 1 in three strains of mice immunized with a 22 amino acid peptide of gp41 expressed on the surface of a plant virus. Vaccine. 1996; 14(8):799–810. PMID: 8817828.